Tag Archives: inhibitor

ESMO Virtual Congress 2020: Libtayo positive pivotal data offer hope for the treatment of advanced basal cell carcinoma, a difficult-to-treat cancer

Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial 31% objective response rate seen in trial patients, and an estimated 85% of responses … Read the full press release

Novartis announces EC approval for Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for adjuvant treatment of BRAF V600 mutation-positive melanoma

Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients   More than 50% of stage III melanoma patients are likely to recur to stage IV during their lifetime … Read the full press release

Novartis: the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 has met the primary endpoint

SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase inhibitor with or without a CDK4/6 inhibitor[1] Approximately 40% of HR+ advanced breast cancer … Read the full press release

AstraZeneca: Japan approval for Lynparza (olaparib) tablets for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer

Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status CAMBRIDGE, 22-Jan-2018 — /EuropaWire/ — AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, … Read the full press release

Biotie Therapies started clinical study evaluating nepicastat in cocaine dependence

Turku, 29-5-2013 — /europawire.eu/ — Biotie Therapies today announced the start of a Phase 2 clinical study evaluating nepicastat (SYN117) in cocaine dependence. The National Institute on Drug Abuse (NIDA) at the US National Institutes of Health is funding the conduct … Read the full press release